These observations suggest that intratumoral Tregs are important to the initiation and maintenance of the exhausted phenotype of tumor-associated T cells, and therefore Treg targeting with ASO FOXP3 may overcome resistance to checkpoint inhibitors therapies, leading to enhanced anti-tumor responses (70, 71). The gene discussed is FOXP3; the disease is neoplasm.